{"title":"Vaccines and treatments for Zika virus infection: patent status, triumphs and challenges.","authors":"Sandro G Viveiros Rosa, Wilson C Santos","doi":"10.4155/ppa-2021-0014","DOIUrl":"https://doi.org/10.4155/ppa-2021-0014","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 5","pages":"209-213"},"PeriodicalIF":1.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39389094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A nontoxic ionic liquid composition for the delivery of biological macromolecular anions across the skin barrier.","authors":"Neeraj Kumar, Balraj Saini, Rajwinder Kaur","doi":"10.4155/ppa-2021-0012","DOIUrl":"https://doi.org/10.4155/ppa-2021-0012","url":null,"abstract":"<p><p>The development of biocompatible ionic liquids is needed in order to explore their vastly underutilized pharmaceutical potential. US10912834 patent discloses ionic liquids comprising macromolecular biological anions and alkylated cations, which provides enhanced dermal delivery and cell internalization of the large biological anions. The studies of <i>ex vivo</i> permeation through excised pig skin indicated significantly higher skin penetration of percent dose and enhanced drug internalization was achieved using these ionic liquids. Although, the patent advances an infant field of biological macromolecule-based ionic liquids, the evaluation of these claimed ionic liquids relies only on the <i>in vivo</i> cytotoxicity data and <i>ex vivo</i> skin permeation behavior. Exhaustive studies, including dermatokinetic evaluation and long-term animal toxicity experiments, should be performed in order to unravel the potential of the aforementioned ionic liquids.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 4","pages":"191-194"},"PeriodicalIF":1.3,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39289974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Patentability challenges associated with emerging pharmaceutical technologies.","authors":"Srishti Aggarwal, Amrish Chandra","doi":"10.4155/ppa-2021-0009","DOIUrl":"https://doi.org/10.4155/ppa-2021-0009","url":null,"abstract":"<p><p>According to the recent patent filing trends, it has been observed that certain pharmaceutical technologies are more popular than others and are commonly referred to as emerging technologies. The emerging technologies in the pharmaceutical sector include artificial intelligence, big data and certain advanced biological therapies such as personalized medicine and stem cell therapy. These trends have various applications in the medicine and healthcare industry. Since these technologies are relatively new and each of them is very unique in its own way, current patent laws are inadequate to deal with the complex challenges associated with them. A brief analysis of the challenges associated with these emerging technologies and their applications is discussed in this paper.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 4","pages":"195-207"},"PeriodicalIF":1.3,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39177129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Patent highlights February-March 2021.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2021-0010","DOIUrl":"10.4155/ppa-2021-0010","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 4","pages":"183-190"},"PeriodicalIF":1.8,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39155477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Patent highlights December 2020-January 2021.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2021-0005","DOIUrl":"10.4155/ppa-2021-0005","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 3","pages":"103-110"},"PeriodicalIF":1.8,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38923642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Slobodan M Janković, Nenad Marković, Tanja Luković
{"title":"Treating of focal epilepsy: a patent review.","authors":"Slobodan M Janković, Nenad Marković, Tanja Luković","doi":"10.4155/ppa-2021-0008","DOIUrl":"https://doi.org/10.4155/ppa-2021-0008","url":null,"abstract":"<p><p>Focal epilepsy is one of the most frequent specific type of epilepsies, with 30% treatment-resistant patients. There are several directions researchers can follow to improve existing treatment of focal epilepsy: synthesis of new compounds with anticonvulsant activity, repurposing drugs approved for other indications, finding drugs targeted to specific genetic and biochemical defects that underlie focal epilepsy syndromes, development of viral vectors for specific gene therapy, creation of devices and methods for suppression of seizures by electrostimulation and development of methods to increase safety of epilepsy surgery. Improvement of efficacy and safety of current therapies is necessary, as well as developing targeted treatment of genetic epilepsy syndromes that will not only suppress seizures, but stop further epileptogenesis.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 3","pages":"165-173"},"PeriodicalIF":1.3,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38972959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}